Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003).

Aim: The aim is to report the long-term outcomes of preoperative cisplatin and fluorouracil plus docetaxel (DCF) vs Adriamycin (ACF) for resectable esophageal squamous cell carcinoma (ESCC). Previously, this trial showed that DCF is associated with prolonged recurrence-free survival (RFS).

Methods: Patients were randomly assigned to two cycles of ACF (35 mg/m of Adriamycin, 70 mg/m of cisplatin intravenously on day 1, and 700 mg/m of fluorouracil infusion for 7 days) every 4 weeks or DCF (70 mg/m of docetaxel, 70 mg/m of cisplatin intravenously on day 1, and 700 mg/m of fluorouracil infusion for 5 days) every 3 weeks, followed by surgery.

[Therapeutic Implication Targeting for Cancer Stem Cells].

Cancer has been viewed as a heterogeneous population of cells.While the large majority of cells that constituting tumors are differentiated, and eventually stop dividing, only a minority population of cells, termed cancer stem cells, is capable of unlimited self-renewal and multi-differentiation, just like somatic stem cells in normal tissues.Cancer stem cells have been identified in a variety of cancers of the blood, brain, stomach, colon, and pancreas.

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.

Background: A trial was conducted to evaluate the feasibility, efficacy, and safety of biweekly administration of irinotecan, a novel topoisomerase I inhibitor, for patients with metastatic breast cancer (MBC) previously treated with either anthracycline-based or taxane-based chemotherapy.

Methods: Eligible patients were HER2-negative, had a performance status of 0 to 2, and had been treated previously with either anthracyclines or taxanes for MBC. Patients received irinotecan intravenously at 150 mg/m(2) on days 1 and 15 every 4 weeks.